Various modifications and alterations to the present invention may be appreciated based on a review of this disclosure. These changes and additions are intended to be within the scope and spirit of the invention as defined by the following claims.

AMENDMENTS TO THE ABSTRACT:

Please amend page 1, paragraph 1, to read as follows:

[ABSTRACT]

- - ABSTRACT OF THE DISCLOSURE - -

A kit for [the] treatment of retinitis pigmentos[a]is containing the enzymes glutathione peroxidase, prolidase, glucose-6-phosephate dehydrogenase and, optionally, aldose reductase in aliquot parts and interactive quantities appropriate for administering [said] the enzymes in accordance with a predefined time sequence.

AMENDMENTS TO THE CLAIMS:

Please amend page 12, paragraph 1, to read as follows:

- - WHAT IS CLAIMED IS: - -

[CLAIMS]

The following listing of claims will replace all prior versions, and listings, of claims in the captioned Application:

LISTING OF CLAIMS:

Claim 1 (currently amended) A pharmaceutical kit for [the] treatment of retinitis pigmentos[a]is containing the enzymes glutathione peroxidase (Enzyme A), prolidase (Enzyme B), glucose-6-phosphate dehydrogenase (Enzyme C) and, optionally, aldose reductase (Enzyme D) in aliquot parts and interactive quantities appropriate for administering:

a) Enzyme A at a concentration [comprised between] generally within a range of 0.03 and 0.05 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;

b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration generally within a range of 5 [to] and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;

c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration generally within a range of 7 [to] and 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.

d) Enzyme D, starting from the month following the last administration of Enzyme C, at a concentration generally within a range of 5 [to] and 7 U.I.

in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.

Claim 2 (currently amended) [A] The kit [in accordance with] set forth in [C]claim 1, wherein the concentration of Enzyme A is about 0.04 U.I. in approximately 0.4 ml of physiological solution, the concentration of Enzyme B is about 6.67 U.I. in approximately 0.4 ml of physiological solution and the concentration of Enzyme C is about 8 U.I. in around 0.4 ml of physiological solution, the concentration of optional Enzyme D being equal to about 8 U.I. in approximately 0.4 ml of physiological solution.

Claim 3 (currently amended) A kit [in accordance with] set forth in [C]claim 1 [or Claim 2], wherein [said] the kit comprises [said] the enzymes in lyophilised form, in quantities sufficient for at least one series of administrations of from a) to c) and, optionally, also d), subdivided into aliquot parts containing [–], for each enzyme, [–] a selected quantity of enzyme sufficient for the constitution of [said] the aliquot parts.

Claim 4 (currently amended) A kit [in accordance with any one of] set forth in [C]claim[s] 1 [to 3], wherein [said] the kit comprises [said] the enzymes in lyophilised form subdivided into one or more aliquot parts, each containing from about 0.04 U.I. to about 0.72 U.I. of Enzyme A, from about 0.67 to around 120 U.I. of Enzyme B, from approximately 8 to about 144 U.I. of Enzyme C and, optionally, from around 8 to

about 144 U.I. of Enzyme D, and, optionally, three or more aliquot parts of physiological solution generally within a range of [from] 0.4 [to] and 7.2 ml each.

Claim 5 (currently amended) Use of the enzymes glutathione peroxidase (Enzyme A), prolidase (Enzyme B), glucose-6-phosphate dehydrogenase (Enzyme C) and, optionally, aldose reductase (Enzyme D) for the preparation of a pharmaceutical composition in kit form for [the] treatment of retinitis pigmentos[a]is by [means of] injection into the retrobulbar tissue, [said] the kit containing [said] the enzymes in aliquot parts and interactive quantities appropriate for administering:

a) Enzyme A at a concentration [comprised between] generally within a range of 0.03 and 0.05 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;

b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration generally within a range of 5 [to] and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;

c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration generally within a range of 7 [to] and 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.

d) Enzyme D, starting from the month following the last administration of Enzyme C, at a concentration generally within a range of 5 [to] and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye.

Claim 6 (currently amended) Use of the enzymes [in accordance with] set forth in [C]claim [6] 5, wherein concentration of Enzyme A is about 0.04 U.I. in approximately 0.4 ml of physiological solution, the concentration of Enzyme B is about 6.67 U.I. in around 0.4 ml of physiological solution and the concentration of Enzyme C is approximately 8 U.I. in about 0.4 ml of physiological solution, the concentration of optional Enzyme D being equal to about 8 U.I. in about 0.4 ml of phisiological solution.

Claim 7 (currently amended) Use of the enzymes [in accordance with] set forth in [C]claim[s] 5 [or 6], wherein [said] the kit comprises [said] the enzymes in lyophilised form, in quantities sufficient for at least one series of administrations of from a) to c) and, optionally, also d), subdivided into aliquot parts containing [–], for each enzyme [–], a quantity of enzyme sufficient for the constitution of [said] the aliquot parts.

Claim 8 (currently amended) Use of the enzymes [in accordance with any one of the preceding] set forth in claim[s] 5, wherein [said] the kit comprises [said] the enzymes in lyophilised form subdivided into one or more aliquot parts, each containing [from] generally within a range of 0.04 [U.I. to] and 0.72 U.I. of Enzyme A, from about

0.67 U.I. to about 120 U.I. of Enzyme B, from about 8 U.I. to about 144 U.I. of Enzyme C and, optionally, from about 8 U.I. to about 144 U.I. of Enzyme D, and, optionally, three or more aliquot parts of physiological solution generally within a range of [from] 0.4 [to] and 7.2 ml each.

Claim 9 (currently amended) A method for [the] treatment of retinitis pigmentos[a]is that envisages the administration by [means of] injection into the retrobulbar tissue of:

a) Enzyme A at a concentration [comprised between] generally within a range of 0.03 and 0.05 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;

b) Enzyme B, starting from the month following the last administration of Enzyme A, at a concentration generally within a range of 5 [to] and 7 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;

c) Enzyme C, starting from the month following the last administration of Enzyme B, at a concentration generally within a range of 7 [to] and 9 U.I. in about 0.4 ml of physiological solution for approximately three consecutive days, at monthly intervals, for about three months and for each eye;